Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
about
Thalidomide for the treatment of idiopathic myelofibrosis.Modern management of myelofibrosis.Immunomodulatory agents in myelofibrosis.Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Advances in the treatment for haematological malignancies.Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases.Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.Vascular endothelial growth factor A (VEGFA) expression in mycosis fungoides
P2860
Q33359542-E06D826E-C01F-4D28-9647-77EA19925A9AQ33365122-2BB0D2DB-7DAD-454F-B8B1-FB7AD1E9C9A6Q33401615-3620ECC1-54F2-4349-BE8D-4C2E3D113611Q35994847-AF8B0A88-EDF1-4A7C-A1F3-54EB24037881Q36047069-7646AD6A-67B6-4E71-8A8D-EF7D485B6E02Q36171864-6CB20765-65BF-4CD3-9B21-C4FE52883547Q36429723-F05AFD33-BFB8-42DC-8AB0-8158B38981C9Q39028883-04EEEF7D-62B3-4010-9D32-1C4ACBCD2DD7Q39716869-73F96D41-8F63-40DB-B58D-BB7A60EB15E1Q44529465-8F7256B9-72D5-4BF1-AAC8-088F149704D0Q46600666-F913B6D8-A842-4554-B967-75BCFDC85EA9Q46979566-84BBFC86-3D00-4F05-888E-9A8781B2DFBCQ47288480-8D4263DA-2709-4B1D-9D4A-61CB35187D0AQ51052766-36AB4A02-3F7B-42C3-BF84-651C3A2E07DCQ56971634-2448FA4A-A6F0-4A7A-A039-B18957FCB72E
P2860
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@ast
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@en
type
label
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@ast
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@en
prefLabel
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@ast
Clinical efficacy and antiangi ...... oid metaplasia. A pilot study.
@en
P2093
P356
P1433
P1476
Clinical efficacy and antiangi ...... loid metaplasia. A pilot study
@en
P2093
Baccarani M
Malagola M
Martinelli G
Piccaluga PP
P2888
P304
P356
10.1038/SJ.LEU.2402596
P577
2002-09-01T00:00:00Z
P5875
P6179
1049779408